Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

This study tested whether a new combination of drugs (bemarituzumab plus anlotinib) works better than the standard treatment (tislelizumab) for people with extensive-stage small cell lung cancer. The trial was stopped early and included 40 adults aged 18-75. The goal was to see i…

This study tested a new drug (TQB2450) combined with chemotherapy, with or without another drug (anlotinib), as a first treatment for advanced endometrial cancer or uterine sarcoma. The goal was to see if the combination could shrink tumors. The trial was stopped early, but the r…

This early-stage study tested a new drug combination (TQB2223 plus penpulimab) in 22 adults with advanced liver cancer. The goal was to see if the treatment was safe and could shrink tumors. However, the trial was terminated early, so results are limited.

This study tested two experimental tablets (TQ05105 and TQB3909) together in 21 adults with moderate- or high-risk myelofibrosis, a serious bone marrow disorder. The goal was to find the safest dose and see if the combination could shrink an enlarged spleen. The trial was termina…

This study tested a new drug (TQB3616) combined with either anlotinib or standard chemotherapy in 21 people with advanced lung cancer. The goal was to see if the combination could shrink tumors or slow the disease. The trial was stopped early, so results are limited and no clear …

This study tested a new drug, TQ05105, in 13 people who had severe graft-versus-host disease (aGVHD) after a stem cell transplant and did not respond to steroids. The goal was to see if the drug is safe and can help control the disease. The study was stopped early, so results are…

This study tested a new drug called TQB3616 for people with a rare type of fat tissue cancer called dedifferentiated liposarcoma that could not be removed by surgery. The goal was to see if the drug could slow cancer growth compared to a placebo. The trial was stopped early after…

This study tested a new drug (TQB3912) combined with standard treatments (fulvestrant and TQB3616) in people with advanced HR-positive, HER2-negative breast cancer. The goal was to find the best dose and see if the combination helps shrink tumors or slow the disease. Only 8 peopl…

This early-stage study tested a new drug called TQB3720 in men with advanced prostate cancer that had stopped responding to standard treatments. The goal was to find the safest dose and see how the drug moves through the body. The trial was terminated early, so results are limite…